GlaxoSmithKline (GSK) Issues Quarterly Earnings Results

Share on StockTwits

GlaxoSmithKline (LON:GSK) posted its earnings results on Wednesday. The company reported GBX 52.70 ($0.70) earnings per share for the quarter, Bloomberg Earnings reports. GlaxoSmithKline had a return on equity of 348.10% and a net margin of 9.36%.

GlaxoSmithKline traded up GBX 17.20 ($0.23), hitting GBX 1,553.40 ($20.56), during trading on Friday, according to Marketbeat Ratings. 8,539,369 shares of the stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($16.35) and a 1-year high of GBX 1,724.50 ($22.83).

The company also recently declared a dividend, which will be paid on Thursday, October 11th. Shareholders of record on Thursday, August 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 9th.

In other news, insider Philip R. Hampton purchased 2,810 shares of the business’s stock in a transaction on Wednesday, July 25th. The shares were bought at an average price of GBX 1,557 ($20.61) per share, with a total value of £43,751.70 ($57,910.92).

Several equities research analysts recently weighed in on the company. Berenberg Bank boosted their target price on GlaxoSmithKline from GBX 1,780 ($23.56) to GBX 1,790 ($23.69) and gave the stock a “buy” rating in a research note on Wednesday, April 25th. Credit Suisse Group set a GBX 1,450 ($19.19) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Monday, July 16th. Deutsche Bank set a GBX 1,525 ($20.19) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Monday, July 9th. Cfra set a GBX 1,550 ($20.52) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. set a GBX 1,550 ($20.52) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday, July 10th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of GBX 1,533.82 ($20.30).

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Dividend

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

FY2019 Earnings Estimate for Home Depot Inc Issued By Gabelli
FY2019 Earnings Estimate for Home Depot Inc Issued By Gabelli
Walmart Inc Expected to Earn Q1 2020 Earnings of $1.10 Per Share
Walmart Inc Expected to Earn Q1 2020 Earnings of $1.10 Per Share
Polarityte  Upgraded at BidaskClub
Polarityte Upgraded at BidaskClub
Rockwell Medical  Downgraded by Zacks Investment Research to “Sell”
Rockwell Medical Downgraded by Zacks Investment Research to “Sell”
Amicus Therapeutics  Downgraded by BidaskClub
Amicus Therapeutics Downgraded by BidaskClub
Leerink Swann Weighs in on Amgen, Inc.’s FY2019 Earnings
Leerink Swann Weighs in on Amgen, Inc.’s FY2019 Earnings


© 2006-2018 Ticker Report. Google+.